The national incidence of PML in Sweden, 1988-2013Show others and affiliations
2018 (English)In: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 90, no 6, p. E498-E506Article in journal (Refereed) Published
Abstract [en]
Objective: To investigate the incidence of progressive multifocal leukoencephalopathy (PML) and patient characteristics in Sweden between 1988 and 2013.
Methods: All PML diagnoses in Sweden between 1988 and 2013 were identified in the National Patient Register. Information to validate the diagnosis and patient characteristics was obtained from medical records.
Results: Medical record review classified 108 out of 250 patients (43%) as definite (n = 84), probable (n = 4), or possible (n = 20) PML according to diagnostic criteria. Accurate diagnoses were more common in records obtained from neurology departments (82% of patients seen in neurology departments) compared with other departments (31%) (p < 0.001). The incidence of PML increased from a largely stable level at 0.026 (95% confidence interval [CI] 0.021-0.031) per 100,000 individuals per year during 1988-2010 to 0.11 (95% CI 083-0.137) during 2011-2013, during which time there was a notable increase (p < 0.001). Hematologic malignancies (n = 34), HIV/AIDS (n = 33), and autoimmune disease (n = 23) were the most common underlying diseases. Treatment with a monoclonal antibody prior to PML diagnosis was identified in 26 patients.
Conclusion: An increased incidence of PML in Sweden was observed and coincided with the prior use of monoclonal antibody treatment. The high level of misdiagnosis emphasizes the importance of immediate contact with a neurology center upon suspicion of PML.
Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2018. Vol. 90, no 6, p. E498-E506
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-66935DOI: 10.1212/WNL.0000000000004926ISI: 000427800200007PubMedID: 29321229OAI: oai:DiVA.org:oru-66935DiVA, id: diva2:1205489
Funder
The Swedish Brain Foundation
Note
Funding Agencies:
F. Hoffmann-La Roche Ltd.
Stockholm County Council
Swedish Medical Research Council
Karolinska Institutet
2018-05-142018-05-142023-06-29Bibliographically approved